ID

34401

Beskrivning

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib; ODM derived from: https://clinicaltrials.gov/show/NCT01514448

Länk

https://clinicaltrials.gov/show/NCT01514448

Nyckelord

  1. 2019-01-17 2019-01-17 -
Rättsinnehavare

see on clinicaltrials.gov

Uppladdad den

17 januari 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
Beskrivning

ID.1

Datatyp

boolean

progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
Beskrivning

ID.2

Datatyp

boolean

patients scheduled for treatment with everolimus.
Beskrivning

ID.3

Datatyp

boolean

patients with at least one measurable lesion at baseline.
Beskrivning

ID.4

Datatyp

boolean

Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
Beskrivning

ID.5

Datatyp

boolean

patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
Beskrivning

ID.6

Datatyp

boolean

patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
Beskrivning

ID.7

Datatyp

boolean

patients unwilling or unable to comply with the protocol.
Beskrivning

ID.8

Datatyp

boolean

other protocol-defined inclusion/exclusion criteria may apply.
Beskrivning

ID.9

Datatyp

boolean

Similar models

Eligibility Metastatic Renal Cell Carcinoma (mRCC) NCT01514448

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
patients with advanced renal cell carcinoma of a histological or cytological confirmation of clear cell renal carcinoma.
boolean
ID.2
Item
progression during or after a treatment with sunitinib or pazopanib given in a 1st line treatment situation for mrcc.
boolean
ID.3
Item
patients scheduled for treatment with everolimus.
boolean
ID.4
Item
patients with at least one measurable lesion at baseline.
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
patients who have received >1 prior systemic treatment for their metastatic rcc. prior systemic treatment in an adjuvant setting is allowed.
boolean
ID.6
Item
patients who have previously received systemic mtor inhibitors (e.g. sirolimus, temsirolimus, everolimus).
boolean
ID.7
Item
patients who are using other investigational agents or who had received investigational drugs ≤ 2 weeks prior to study treatment start.
boolean
ID.8
Item
patients unwilling or unable to comply with the protocol.
boolean
ID.9
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial